News >

Cristofanilli Calls for More Effective Options in ESR1-Mutant Breast Cancer

Kristi Rosa
Published: Monday, Nov 04, 2019

Massimo Cristofanilli, MD

Massimo Cristofanilli, MD

Despite advances made in disease biology and detection, treatment for patients with ESR1-mutated, estrogen receptor (ER)–positive, HER2-negative breast cancer continues to be an area of unmet need, according to Massimo Cristofanilli, MD. As more patients develop resistance to available agents, he adds, the need for novel safer and more effective therapies is emphasized.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication